Zobrazeno 1 - 10
of 27
pro vyhledávání: '"B. E. Stewart"'
Autor:
Rebecca J. Loomis, Anthony T. DiPiazza, Samantha Falcone, Tracy J. Ruckwardt, Kaitlyn M. Morabito, Olubukola M. Abiona, Lauren A. Chang, Ria T. Caringal, Vladimir Presnyak, Elisabeth Narayanan, Yaroslav Tsybovsky, Deepika Nair, Geoffrey B. Hutchinson, Guillaume B. E. Stewart-Jones, Lisa A. Kueltzo, Sunny Himansu, John R. Mascola, Andrea Carfi, Barney S. Graham
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Nipah virus (NiV) represents a significant pandemic threat with zoonotic transmission from bats-to-humans with almost annual regional outbreaks characterized by documented human-to-human transmission and high fatality rates. Currently, no vaccine aga
Externí odkaz:
https://doaj.org/article/1645dea2614f43f6baad4345b571338b
Autor:
Rebecca J. Loomis, Guillaume B. E. Stewart-Jones, Yaroslav Tsybovsky, Ria T. Caringal, Kaitlyn M. Morabito, Jason S. McLellan, Amy L. Chamberlain, Sean T. Nugent, Geoffrey B. Hutchinson, Lisa A. Kueltzo, John R. Mascola, Barney S. Graham
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Licensed vaccines or therapeutics are rarely available for pathogens with epidemic or pandemic potential. Developing interventions for specific pathogens and defining generalizable approaches for related pathogens is a global priority and inherent to
Externí odkaz:
https://doaj.org/article/a1bbbff82f3d4c11bf226a9b4c218342
Autor:
Baoshan Zhang, Lei Chen, Chiara Silacci, Michelle Thom, Jeffrey C. Boyington, Aliaksandr Druz, M. Gordon Joyce, Efrain Guzman, Wing- Pui Kong, Yen-Ting Lai, Guillaume B. E. Stewart-Jones, Yaroslav Tsybovsky, Yongping Yang, Tongqing Zhou, Ulrich Baxa, John R. Mascola, Davide Corti, Antonio Lanzavecchia, Geraldine Taylor, Peter D. Kwong
Publikováno v:
npj Vaccines, Vol 2, Iss 1, Pp 1-11 (2017)
Respiratory disease: A bovine model for respiratory syncytial virus vaccines Researchers have produced a vaccine that protects against bovine respiratory syncytial virus (bRSV) in calves, with implications for humans. An international team comprising
Externí odkaz:
https://doaj.org/article/001a5cd8bf13451aaee8ecd1a3d59fa6
Autor:
Joseph R Francica, Richard Laga, Geoffrey M Lynn, Gabriela Mužíková, Ladislav Androvič, Baptiste Aussedat, William E Walkowicz, Kartika Padhan, Ramiro Andrei Ramirez-Valdez, Robert Parks, Stephen D Schmidt, Barbara J Flynn, Yaroslav Tsybovsky, Guillaume B E Stewart-Jones, Kevin O Saunders, Faezzah Baharom, Constantinos Petrovas, Barton F Haynes, Robert A Seder
Publikováno v:
PLoS Biology, Vol 17, Iss 6, p e3000328 (2019)
Peptide immunogens provide an approach to focus antibody responses to specific neutralizing sites on the HIV envelope protein (Env) trimer or on other pathogens. However, the physical characteristics of peptide immunogens can limit their pharmacokine
Externí odkaz:
https://doaj.org/article/1babd03009874df1a6a109bd5ebd2b16
Autor:
Mallika Sastry, Anita Changela, Jason Gorman, Kai Xu, Gwo-Yu Chuang, Chen-Hsiang Shen, Cheng Cheng, Hui Geng, Sijy O'Dell, Li Ou, Reda Rawi, Mateo Reveiz, Guillaume B. E. Stewart-Jones, Shuishu Wang, Baoshan Zhang, Tongqing Zhou, Andrea Biju, Michael Chambers, Xuejun Chen, Angela R. Corrigan, Bob C. Lin, Mark K. Louder, Krisha McKee, Alexandra F. Nazzari, Adam S. Olia, Danealle K. Parchment, Edward K. Sarfo, Tyler Stephens, Jonathan Stuckey, Yaroslav Tsybovsky, Raffaello Verardi, Yiran Wang, Cheng-Yan Zheng, Yuling Chen, Nicole A. Doria-Rose, Adrian B. McDermott, John R. Mascola, Peter D. Kwong
Publikováno v:
Journal of Virology. 97
The HIV-1 fusion peptide has been identified as a site for elicitation of broadly neutralizing antibodies, with prior studies demonstrating that priming with fusion peptide-based immunogens and boosting with soluble envelope (Env) trimers can elicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e8a063ebf785cd936a54769eab586aa
https://doi.org/10.1128/jvi.01604-22
https://doi.org/10.1128/jvi.01604-22
Autor:
Helen M. Parrington, Nurgun Kose, Erica Armstrong, Laura Handal, Summer Diaz, Joseph Reidy, Jinhui Dong, Guillaume B. E. Stewart-Jones, Punya Shrivastava-Ranjan, Shilpi Jain, César G. Albariño, Robert H. Carnahan, James E. Crowe
Sosuga virus (SOSV) is a recently discovered paramyxovirus with a single known human case of disease. There has been little laboratory research on SOSV pathogenesis or immunity, and no approved therapeutics or vaccines are available. Here, we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26f6cfef853cf948e1f74d6c9e622d78
https://doi.org/10.1101/2022.11.17.516973
https://doi.org/10.1101/2022.11.17.516973
Autor:
Jeffrey C Boyington, M Gordon Joyce, Mallika Sastry, Guillaume B E Stewart-Jones, Man Chen, Wing-Pui Kong, Joan O Ngwuta, Paul V Thomas, Yaroslav Tsybovsky, Yongping Yang, Baoshan Zhang, Lei Chen, Aliaksandr Druz, Ivelin S Georgiev, Kiyoon Ko, Tongqing Zhou, John R Mascola, Barney S Graham, Peter D Kwong
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159709 (2016)
Respiratory syncytial virus (RSV) is a significant cause of severe respiratory illness worldwide, particularly in infants, young children, and the elderly. Although no licensed vaccine is currently available, an engineered version of the metastable R
Externí odkaz:
https://doaj.org/article/9fdbd01144bd4280a256c1969d2c1378
Autor:
Guillaume B E Stewart-Jones, Paul V Thomas, Man Chen, Aliaksandr Druz, M Gordon Joyce, Wing-Pui Kong, Mallika Sastry, Cinque Soto, Yongping Yang, Baoshan Zhang, Lei Chen, Gwo-Yu Chuang, Ivelin S Georgiev, Jason S McLellan, Sanjay Srivatsan, Tongqing Zhou, Ulrich Baxa, John R Mascola, Barney S Graham, Peter D Kwong
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0128779 (2015)
Recombinant subunit vaccines should contain minimal non-pathogen motifs to reduce potential off-target reactivity. We recently developed a vaccine antigen against respiratory syncytial virus (RSV), which comprised the fusion (F) glycoprotein stabiliz
Externí odkaz:
https://doaj.org/article/842b18df124241c789b75fea7778ce7c
Autor:
Emma J Bowles, Torben Schiffner, Maximillian Rosario, Gemma A Needham, Meghna Ramaswamy, Joanna McGouran, Benedikt Kessler, Celia LaBranche, Andrew J McMichael, David Montefiori, Quentin J Sattentau, Tomáš Hanke, Guillaume B E Stewart-Jones
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114709 (2014)
Eliciting neutralizing antibodies capable of inactivating a broad spectrum of HIV-1 strains is a major goal of HIV-1 vaccine design. The challenge is that envelopes (Envs) of circulating viruses are almost certainly different from any Env used in a v
Externí odkaz:
https://doaj.org/article/a071416669c946df956c9ce7e4c9c7f5
Autor:
Gülşen Ozkaya Sahin, Emma J Bowles, Joe Parker, Hannes Uchtenhagen, Enas Sheik-Khalil, Stephen Taylor, Oliver G Pybus, Barbro Mäkitalo, Lilian Walther-Jallow, Mats Spångberg, Rigmor Thorstensson, Adnane Achour, Eva Maria Fenyö, Guillaume B E Stewart-Jones, Anna-Lena Spetz
Publikováno v:
PLoS Pathogens, Vol 6, Iss 9, p e1001084 (2010)
Neutralizing antibodies (NAb) able to react to heterologous viruses are generated during natural HIV-1 infection in some individuals. Further knowledge is required in order to understand the factors contributing to induction of cross-reactive NAb res
Externí odkaz:
https://doaj.org/article/3f84311627eb4101b2883fa512727496